A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study of LTG-305 Administered Orally to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male and Female Participants 18 to 55 Years of Age
Latest Information Update: 14 Jul 2025
At a glance
- Drugs LTG 305 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Latigo Biotherapeutics
Most Recent Events
- 04 Jul 2025 Status changed from recruiting to completed.
- 22 May 2025 Planned End Date changed from 31 Mar 2025 to 30 Sep 2025.
- 22 May 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Aug 2025.